Oncoustics

About Oncoustics

Oncoustics’ AI Solutions turn inexpensive Point of Care Ultrasound devices into powerful diagnostic tools for faster, cost effective detection and monitoring of diseases including diseases in the liver, prostate, kidney, breast and thyroid. Our team is made up of experts in AI, Signal Processing, radiology, hepatology, digital health and Ultrasound.

Improves Access and Outcomes

Inexpensive point of care diagnosis and surveillance improves outcomes through early detection and monitoring resulting in effective disease management.

Improves Patient Experience

Fast and efficient test available in any office turning a previously multi-day/week experience with multiple healthcare experts and departments a seamless one stop encounter.

Enhances Productivity

~5 min imaging exam allows MDs, techs and/or nurses to perform liver surveillance rapidly at point of care, without the need for external referral for streamlined workflow and enhanced in clinic productivity.

Reduces Cost and Workload

SaaS (screening as a service) model saves institutional equipment costs and enhances returns on reimbursements.

Our Solution

Oncoustics offers a full liver diagnosis and screening solution, with a 5 minute exam that can be performed by any clinician or clinical staff. Our solution was developed from over 600,000 Rf images and validated on over 2500 patients via our international clinical partners who acquire data via our specific procedures and protocols.

Oncoustics Takes Minutes

Better for Patients:

Early detection saves lives
Increased patient accessibility
Saves patient time and money

Better for Clinicians:

More efficient, increases productivity over SOC, decreases workload/complexity
No referral - keeps patient in practice
Major cost savings over SOC
Additional revenues for your practice via existing CPT codes

In Clinic Rapid Diagnosis and Surveillance

Data not used in Grayscale Bmode Imaging in US to Deliver Point-of-Care Diagnosis:

Rapid 5-10 min PoC exam
Comes installed on a PoC device and is ready to go
No integration into existing institutional IT/PACS necessary
Unique use of additional data stream for AI/ML biomarkers
Designed with acquisition guidance/does not require expert sonographers or radiologists
Automated analysis and enhanced visualization/disease maps
Ongoing international data collection at 6 clinics; 5 additional centers planned for 2020 Current early results = 85-90+% accuracies; targeting 99%

Technology

Tissue Characterizaion in the Palm of your Hands

Oncoustics’s Pipeline of Pocket Sized Diagnostic Solutions are minimizing the need for invasive biopsy and expensive imaging in detection and characterization* of disease:

Surveillance, Diagnosing and staging tissue pathologies (i.e Liver, Kidney)
Surveillance, Diagnosis and staging of cancers
Guiding treatment, biopsy, ablation and radiation
Supporting drug/treatment development and use (clinical trails to companion device)

*Traditionally applied, tissue characterization require huge investments in pathology (invasive) and/or radiology systems including MRIs, CTs and Ultrasound - and is subject to the qualitative interpretation of experts.

Testimonials

A point of care liver dx solution that provides a rapid bedside exam and yields information on liver fibrosis, steatosis, inflammation and nodule formation, could hugely impact the field of hepatology.

Sam Lee, MD University of Calgary

[Oncoustics’ technique] makes perfect sense to me as the raw data is much richer than that in current medical images…This technique is much easier to use and would benefit millions of at risk patients.

Dr. Chen Fong, MD Past Chair of Radiology, University of Calgary

“The Oncoustics’ technology broadens our options and could be performed in the clinic or in an outpatient center. As applications and strategies evolve, there is huge potential for enhanced, non-invasive tissue characterization.”

Dr. Anand Patel, MD Providence Little Company of Mary Medical Center - Torrance

A point of care tool to help assess liver diseases such as fibrosis and steatosis within minutes could help improve outcomes and reduce clinical workload for physicians and techs. This would be a valuable tool for initial surveillance in rural centres.

DR. AIJAZ AHMED, MD Stanford Medical Center

As a primary care physician, I have the tools to screen my patients with diabetes for high risk end organ damage, including cardiovascular risk, retinopathy, nephropathy, and neuropathy. A tool to screen for NASH/NAFLD is equally important, and I love that the OnX would allow me to screen and counsel the patient within a single encounter.

Dr. Matthew Sakumoto MD, UCSF, CPMC

The biggest challenge we face is in identifying whom amongst [our] many patients have advanced fibrosis and are at risk for liver failure. Point of care tools would be particularly useful in this respect.

Dr. Gary F. Lewis MD FRCP, Banting and Best Diabetes Centre, UoT